PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
- PMID: 25915768
- DOI: 10.7326/M15-0920
PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
Comment on
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957. Ann Intern Med. 2015. PMID: 25915661 Review.
Similar articles
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.Ann Intern Med. 2015 Aug 4;163(3):242-3. doi: 10.7326/L15-5118-3. Ann Intern Med. 2015. PMID: 26237759 No abstract available.
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.Ann Intern Med. 2015 Aug 4;163(3):241-2. doi: 10.7326/L15-5118-2. Ann Intern Med. 2015. PMID: 26237758 No abstract available.
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia.Ann Intern Med. 2015 Aug 4;163(3):241. doi: 10.7326/L15-5118. Ann Intern Med. 2015. PMID: 26237757 No abstract available.
-
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957. Ann Intern Med. 2015. PMID: 25915661 Review.
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Prog Cardiovasc Dis. 2015. PMID: 25936907 Review.
Cited by
-
PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid-lowering effects.J Cell Mol Med. 2019 Nov;23(11):7310-7319. doi: 10.1111/jcmm.14586. Epub 2019 Sep 26. J Cell Mol Med. 2019. PMID: 31557388 Free PMC article.
-
Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.Ther Clin Risk Manag. 2017 Aug 3;13:957-965. doi: 10.2147/TCRM.S143008. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28831261 Free PMC article.
-
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.Eur Heart J Suppl. 2017 May;19(Suppl D):D3-D54. doi: 10.1093/eurheartj/sux029. Epub 2017 May 2. Eur Heart J Suppl. 2017. PMID: 28751833 Free PMC article.
-
Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.Lab Invest. 2017 Aug;97(8):935-945. doi: 10.1038/labinvest.2017.47. Epub 2017 May 15. Lab Invest. 2017. PMID: 28504688 Free PMC article.
-
Accuracy of low-density lipoprotein cholesterol estimation at very low levels.BMC Med. 2017 Apr 20;15(1):83. doi: 10.1186/s12916-017-0852-2. BMC Med. 2017. PMID: 28427464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous